Stockreport

Recent Run-Up Provides MAIA Biotechnology With Breathing Room [Seeking Alpha]

MAIA Biotechnology, Inc.  (MAIA) 
PDF The company presented data from its THIO-101 trial at the ASCO 2024 annual meeting, where the response rate was 38% in 3L NSCLC patients receiving 180 mg THIO. MAIA's [Read more]